Barcelona, Spain - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced that it has appointed Dr. Jörg Schüttrumpf Chief Scientific Innovation Officer (CSIO).

As the head of innovation for the entire Grifols Group, Dr. Schüttrumpf will concentrate on accelerating the development of differentiated plasma and non-plasma medicines in key therapeutic areas, building on Grifols' solid innovation pipeline. His scope includes the entire development cycle for new therapies, from discovery to clinical trial programs, as well as the strategic partnerships and advanced technologies - such as artificial intelligence - needed to achieve the company's innovation goals.

Since early 2022 Dr. Schüttrumpf has been Chief Scientific Officer of Biotest AG, where he had been Head of Global Research since 2012 and Head of Research and Development since 2015. Under his scientific leadership the Biotest team developed therapeutics from human plasma as well as recombinant proteins such as monoclonal antibodies. His recent development focus included three innovative plasma proteins. Yimmugo®, a modern version of an immunoglobulin G preparation with a high-yield process and optimized safety features, was approved last year. The other two plasma therapies are fibrinogen and trimodulin. Both have great therapeutic potential and are successfully developed in phase 3 clinical trials.

Dr. Schüttrumpf is a physician scientist specializing in Transfusion Medicine and Hemostaseology with degrees from Goethe University Frankfurt, Albert-Ludwigs-University Freiburg, and IMD Business School. During his career he worked in leading research institutions both in Germany and in the United States.

"Grifols is extremely pleased to have an experienced, accomplished scientist like Jörg as our CSIO to take Grifols innovation to the next level to benefit patients and all stakeholders," said Victor Grifols Deu, Grifols Chief Operating Officer. "We've collaborated with Jörg for more than a year now and look forward to having his knowledge, talent and energy at work for all of Grifols."

In recent years, Grifols has invested in its innovation infrastructure and today has more than 1,200 research staff working together across four global hubs committed to developing potential new therapeutics. In 2021, the company established the Grifols Scientific Innovation Office to unify the company's research and development efforts under one umbrella, ensuring project prioritization and global collaboration across teams. Grifols has recently established important technology partnerships, such as with Google Cloud, to enhance the use of data and new technologies for the benefit of patients.

"Grifols is a leader in the plasma and biotherapeutics industry saving the lives of thousands of patients with its products every day," said Dr. Schüttrumpf. "I am excited to be part of the Grifols team and I am very grateful about the opportunity to lead its development and innovation initiatives into the future."

.

(C) 2023 M2 COMMUNICATIONS, source M2 PressWIRE